A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19
Latest Information Update: 17 Aug 2021
At a glance
- Drugs Zansecimab (Primary)
- Indications COVID-19 pneumonia
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 27 Oct 2020 Status changed from active, no longer recruiting to discontinued for futility.
- 18 Aug 2020 Status changed from recruiting to active, no longer recruiting.
- 17 Aug 2020 Planned End Date changed from 30 Sep 2020 to 30 Nov 2020.